For in vitro diagnostic use. Others Elecsys HE4 IVD Elecsys® HE4 CPS_000482 07 027 478 190 7 027 478 190 07027478190 7027478190 07027478190 HE4 Elecsys E2G 100 Elecsys HE4 04015630940219 Reagents, kits 100 tests cobas e 402/801 true 05 950 929 190 5 950 929 190 05950929190 5950929190 05950929190 HE4 Elecsys cobas e 100 Elecsys HE4 04015630929641 Reagents, kits 100 tests cobas e 411/601/602 true 07027478500 Elecsys HE4 en 7 FF000000059B640E FF00000004CACB0E 07027478190 07027478214 9494 cobas e 402 2497 cobas e 801 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the quantitative determination of HE4 in human serum and plasma. The assay is used as an aid in monitoring recurrence or progressive disease in patients with epithelial ovarian cancer. Serial testing for patient HE4 values should be used in conjunction with other clinical findings used for monitoring ovarian cancer.It is further intended to be used in conjunction with the Elecsys CA 125 II assay as an aid in estimating the risk of epithelial ovarian cancer in premenopausal and postmenopausal women presenting with pelvic mass. The results must be interpreted in conjunction with other methods in accordance with standard clinical management guidelines.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 07027478500 Elecsys HE4 en 8 FF000000076A7F0E FF00000004BD320E 07027478214 07027478190 9494 cobas e 402 2497 cobas e 801 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the quantitative determination of HE4 in human serum and plasma. The assay is used as an aid in monitoring recurrence or progressive disease in patients with epithelial ovarian cancer. Serial testing for patient HE4 values should be used in conjunction with other clinical findings used for monitoring ovarian cancer.It is further intended to be used in conjunction with the Elecsys CA 125 II assay as an aid in estimating the risk of epithelial ovarian cancer in premenopausal and postmenopausal women presenting with pelvic mass. The results must be interpreted in conjunction with other methods in accordance with standard clinical management guidelines.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en ms_05950929190 Elecsys HE4 en 11 FF000000045ECA0E FF000000000C530E 05950929190 2325 cobas e 602 619 cobas e 601 618 cobas e 411 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the quantitative determination of HE4 in human serum and plasma. The assay is used as an aid in monitoring recurrence or progressive disease in patients with epithelial ovarian cancer. Serial testing for patient HE4 values should be used in conjunction with other clinical findings used for monitoring ovarian cancer.It is further intended to be used in conjunction with the Elecsys CA 125 II assay as an aid in estimating the risk of epithelial ovarian cancer in premenopausal and postmenopausal women presenting with pelvic mass. The results must be interpreted in conjunction with other methods in accordance with standard clinical management guidelines.The electrochemiluminescence immunoassay “ECLIA” is intended for use on Elecsys and cobas e immunoassay analyzers. en

User profile

Select your user profile

Elecsys^® HE4

Overview

Ordering information

Technical documents

Compatible products

Related products

Contact us